Clinical trial NCT03392896: Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
Official title: A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Primary Hyperoxaluria
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2018-01-08
Enrollment: 43
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two-arm (active and placebo), single-blind, SAD period (Group A, HVs) followed by open-label, SAD period (Group B, PH1 and PH2 patients).
Primary purpose: TREATMENT

Brief summary: This is a double-blind, placebo-controlled, dose escalation trial of DCR-PHXC in Healthy Volunteers (HVs) and patients with Primary Hyperoxaluria (PH). Once safety has been established in HV, PH patients with a confirmed diagnosis of PH1 and PH2 will be enrolled across multiple dosing cohorts. The study design will allow enrollment of PH patient cohorts at a given dose level once safety has been demonstrated in HV at that dose level. The study will be conducted in two parts: Part A: Single ascending dose (SAD) in HV; Part B: SAD in patients with PH1 and PH2 (lagging Part A by 1 dose level cohort).


Eligibility criteria: Group A (HVs) Major Inclusion Criteria:

* Willing and able to provide informed consent and comply with study requirements.
* Male or female subjects between 18 and 55 years of age, inclusive.
* Subject must have a body mass index (BMI) 19.0 to 32 kg/m2, inclusive.
* Non-smokers, at least 1-month tobacco free, and willing to remain tobacco free through end of study (EOS).
* Women of child bearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception.

Group A (HVs) Major Exclusion Criteria:

* Presence of any medical condition, including but not limited to: Severe intercurrent illness, known causes of active liver disease.
* Routine or chronic use of more than 3 grams of acetaminophen (Tylenol) daily.
* History of kidney stones.
* Use of any investigational agent within 90 days before the first dose of study medication.
* History of donation of more than 450 mL of blood within 90 days prior to dosing in the clinical research center or planned donation less than 30 days after receiving Investigational Medicinal Product (IMP).
* Plasma or platelet donation within 7 days of dosing and through EOS.
* History of reactions to an oligonucleotide-based therapy.
* Males with female partners who are planning to attempt to become pregnant during this study or within 90 days after last dosing of IMP.
* Plasma or platelet donation within 7 days of dosing and through EOS.

Group B (PH1 and PH2 patients) Major Inclusion Criteria:

* Willing and able to provide informed consent and comply with study requirements.
* Male or female, at least 6 years of age.
* Minimum body weight of 25 kg.
* Genetic confirmation of PH1 and PH2 disease.
* Meet the 24 hour urine oxalate excretion requirements.
* Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2.
* If taking Vitamin B6 (pyridoxine), must have been on stable regimen for at least 4 weeks.

Group B (PH1 and PH2 patients) Major Exclusion Criteria:

* Prior renal and/or hepatic transplantation.
* Currently receiving dialysis.
* Participation in any clinical study where they received an investigational agent within 4 months before enrollment.
* Presence of any medical condition, including but not limited to: Severe intercurrent illness, known causes of active liver disease.
* Liver function test (LFT) abnormalities.
* History of reactions to an oligonucleotide-based therapy.

Primary outcomes:
measure: Number of patients with Treatment-Related Adverse Events (TEAEs)
timeFrame: Part A (SAD in HVs) screening through Day 29; Part B (SAD in PH patients) screening through Day 57
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
city: Bron
country: France
facility: Centre d'Investigation Clinique - CIC 1407 - Hospices Civils de Lyon
city: Bonn
country: Germany
facility: Universitätsklinikum Bonn-Institut für Klinische Chemie und Klinische Pharmakologie
city: Amsterdam
country: Netherlands
facility: University of Amsterdam
city: Birmingham
country: United Kingdom
facility: Queen Elizabeth Hospital Birmingham
city: Birmingham
country: United Kingdom
facility: Birmingham Children's Hospital NHS Trust
city: Wales
country: United Kingdom
facility: Clinical Trial Site
Study officials:
References: